TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank63
3Y CAGR-37.5%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-37.5%/yr
Quarterly compound
Percentile
P63
Within normal range
vs 3Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.42% |
| Q3 2025 | 2.41% |
| Q2 2025 | 11.49% |
| Q1 2025 | -37.12% |
| Q4 2024 | 1.81% |
| Q3 2024 | -6.46% |
| Q2 2024 | 10.39% |
| Q1 2024 | -23.15% |
| Q4 2023 | -396.45% |
| Q3 2023 | 136.40% |
| Q2 2023 | 6.64% |
| Q1 2023 | -47.33% |
| Q4 2022 | 5.83% |
| Q3 2022 | -27.19% |
| Q2 2022 | 33.58% |
| Q1 2022 | -39.94% |
| Q4 2021 | -5.43% |
| Q3 2021 | -27.48% |
| Q2 2021 | -7.46% |
| Q1 2021 | -35.47% |
| Q4 2020 | -26.96% |
| Q3 2020 | -137.97% |
| Q2 2020 | 397.23% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |